Chongqing Taiji Industry(Group)Ltd Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Chongqing Taiji Industry(Group)Ltd wird ein jährliches Gewinn- und Umsatzwachstum von 22.9% bzw. 13.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 22.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 23.2% betragen.

Wichtige Informationen

26.2%

Wachstumsrate der Gewinne

26.2%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	18.5%
Wachstumsrate der Einnahmen	13.5%
Zukünftige Eigenkapitalrendite	22.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Take Care Before Jumping Onto Chongqing Taiji Industry(Group) Co.,Ltd (SHSE:600129) Even Though It's 27% Cheaper

Jul 04

Is Chongqing Taiji Industry(Group)Ltd (SHSE:600129) Using Too Much Debt?

Jul 03

Investors Shouldn't Be Too Comfortable With Chongqing Taiji Industry(Group)Ltd's (SHSE:600129) Earnings

May 02

Is Chongqing Taiji Industry(Group) Co.,Ltd (SHSE:600129) Trading At A 33% Discount?

Mar 18

Chongqing Taiji Industry(Group)Ltd (SHSE:600129) Has A Pretty Healthy Balance Sheet

Feb 28

Gewinn- und Umsatzwachstumsprognosen

SHSE:600129 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	20,650	1,531	1,463	1,921	7
12/31/2025	18,670	1,266	1,534	1,847	7
12/31/2024	16,707	1,010	1,326	1,446	7
6/30/2024	14,388	751	-167	743	N/A
3/31/2024	15,403	834	-185	672	N/A
12/31/2023	15,623	822	-164	672	N/A
9/30/2023	15,677	858	215	865	N/A
6/30/2023	15,929	792	464	1,047	N/A
3/31/2023	15,020	568	1,093	1,663	N/A
12/31/2022	14,127	354	1,249	1,781	N/A
9/30/2022	13,212	-516	393	947	N/A
6/30/2022	12,956	-472	302	841	N/A
3/31/2022	12,386	-527	327	839	N/A
12/31/2021	12,149	-523	59	559	N/A
9/30/2021	12,133	298	164	978	N/A
6/30/2021	11,897	133	158	919	N/A
3/31/2021	11,822	122	-127	657	N/A
12/31/2020	11,208	66	-52	750	N/A
9/30/2020	11,297	-178	-939	40	N/A
6/30/2020	11,248	-150	-869	89	N/A
3/31/2020	11,219	-207	-909	2	N/A
12/31/2019	11,643	-71	-659	327	N/A
9/30/2019	11,937	48	-494	201	N/A
6/30/2019	11,693	105	-580	187	N/A
3/31/2019	11,546	164	-597	180	N/A
12/31/2018	10,689	70	-587	104	N/A
9/30/2018	9,893	166	-637	-124	N/A
6/30/2018	9,475	117	-609	-42	N/A
3/31/2018	9,155	107	N/A	-23	N/A
12/31/2017	8,773	98	N/A	-126	N/A
9/30/2017	8,857	4	N/A	-77	N/A
6/30/2017	8,509	-73	N/A	4	N/A
3/31/2017	8,121	-61	N/A	-82	N/A
12/31/2016	7,952	856	N/A	-108	N/A
9/30/2016	7,488	959	N/A	-125	N/A
6/30/2016	7,211	1,016	N/A	-272	N/A
3/31/2016	7,128	1,131	N/A	-217	N/A
12/31/2015	7,171	232	N/A	-65	N/A
9/30/2015	7,232	-97	N/A	-289	N/A
6/30/2015	7,108	-120	N/A	-284	N/A
3/31/2015	7,035	-263	N/A	-263	N/A
12/31/2014	6,958	-277	N/A	-276	N/A
9/30/2014	6,623	5	N/A	-138	N/A
6/30/2014	6,850	15	N/A	-134	N/A
3/31/2014	6,639	8	N/A	-138	N/A
12/31/2013	6,603	13	N/A	-139	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 600129Das prognostizierte Gewinnwachstum (23.8% pro Jahr) liegt über der Sparquote (2.9%).

Ertrag vs. Markt: 600129Die Erträge des Unternehmens (22.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (22.7% pro Jahr).

Hohe Wachstumserträge: 600129Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 600129Die Einnahmen des Unternehmens (16% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (13.4% pro Jahr).

Hohe Wachstumseinnahmen: 600129Die Einnahmen des Unternehmens (13.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 600129Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (23.2%)

Chongqing Taiji Industry(Group)Ltd Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 19% to CN¥42.83

Recent updates

New minor risk - Share price stability

Chongqing Taiji Industry(Group) Co.,Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 22%

Price target decreased by 19% to CN¥42.83

Second quarter 2024 earnings released: EPS: CN¥0.45 (vs CN¥0.60 in 2Q 2023)

Take Care Before Jumping Onto Chongqing Taiji Industry(Group) Co.,Ltd (SHSE:600129) Even Though It's 27% Cheaper

Is Chongqing Taiji Industry(Group)Ltd (SHSE:600129) Using Too Much Debt?

Chongqing Taiji Industry(Group) Co.,Ltd to Report First Half, 2024 Results on Aug 23, 2024

Investors Shouldn't Be Too Comfortable With Chongqing Taiji Industry(Group)Ltd's (SHSE:600129) Earnings

First quarter 2024 earnings released: EPS: CN¥0.44 (vs CN¥0.42 in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Chongqing Taiji Industry(Group) Co.,Ltd, Annual General Meeting, May 16, 2024

Is Chongqing Taiji Industry(Group) Co.,Ltd (SHSE:600129) Trading At A 33% Discount?

Chongqing Taiji Industry(Group)Ltd (SHSE:600129) Has A Pretty Healthy Balance Sheet

Investor sentiment improves as stock rises 20%

Now 21% undervalued

Chongqing Taiji Industry(Group) Co.,Ltd to Report Fiscal Year 2023 Results on Mar 29, 2024

Investor sentiment improves as stock rises 17%

Third quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.23 in 3Q 2022)

Chongqing Taiji Industry(Group) Co.,Ltd to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.60 (vs CN¥0.17 in 2Q 2022)

New major risk - Share price stability

Investor sentiment improves as stock rises 21%

First quarter 2023 earnings released: EPS: CN¥0.42 (vs CN¥0.04 in 1Q 2022)

Investor sentiment improves as stock rises 16%

Chongqing Taiji Industry(Group) Co.,Ltd (SHSE:600129) agreed to acquire Chongqing Taiji Chinese Medicinal Materials Planting Development Co., Ltd. from Chongqing Taiji Group Co., Ltd. and Chongqing Taiji Medicinal Animal and Plant Resources Development Co., Ltd. for CNY 8.81 million.

Chongqing Taiji Industry(Group) Co.,Ltd (SHSE:600129) agreed to acquire Chongqing Taiji Chinese Medicinal Materials Planting Development Co., Ltd. from Chongqing Taiji Group Co., Ltd. and Chongqing Taiji Medicinal Animal and Plant Resources Development Co., Ltd. for CNY 8.81 million.

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.32 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.11 in 2Q 2021)

Now 21% undervalued

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.011 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.068 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.12 (vs CN¥0.13 loss in FY 2019)

New 90-day low: CN¥12.96

New 90-day low: CN¥13.43

New 90-day low: CN¥15.47

Third quarter earnings released

Chongqing Taiji Industry(Group) Co.,Ltd to Report Q3, 2020 Results on Oct 23, 2020

Chongqing Taiheng Enterprise Management Consulting Co., Ltd. signed an agreement to acquire 59.42% stake in Chengdu Xinhengsheng Real Estate Development Co., Ltd. from Chongqing Taiji Industry(Group) Co.,Ltd (SHSE:600129) for approximately CNY 520 million.

Zuo Hongbo acquired additional 11.7% stake in Southwest Pharmaceutical Co.,Ltd. (SHSE:600666) from Chongqing Taiji Industry (Group) Co.,Ltd (SHSE:600129).

Earnings released

Earnings released

Chongqing Taiji Industry(Group) Co.,Ltd to Report First Half, 2020 Results on Aug 18, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken